214 related articles for article (PubMed ID: 29145816)
1. Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed.
Assayag M; Rouvier P; Gauthier M; Costel G; Cluzel P; Mercadal L; Deray G; Isnard Bagnis C
BMC Cancer; 2017 Nov; 17(1):770. PubMed ID: 29145816
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed-induced acute kidney injury leading to chronic kidney disease.
Chauvet S; Courbebaisse M; Ronco P; Plaisier E
Clin Nephrol; 2014 Dec; 82(6):402-6. PubMed ID: 24424085
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage.
Rombolà G; Vaira F; Trezzi M; Chiappini N; Falqui V; Londrino F
J Nephrol; 2015 Apr; 28(2):187-91. PubMed ID: 24986522
[TBL] [Abstract][Full Text] [Related]
4. Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study.
Visser S; Huisbrink J; van 't Veer NE; van Toor JJ; van Boxem AJM; van Walree NC; Stricker BH; Aerts JGJV
Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30139775
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer.
Vootukuru V; Liew YP; Nally JV
Med Oncol; 2006; 23(3):419-22. PubMed ID: 17018900
[TBL] [Abstract][Full Text] [Related]
6. Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature.
Sbitti Y; Chahdi H; Slimani K; Debbagh A; Mokhlis A; Albouzidi A; Bennani F; Errihani H; Ichou M
J Med Case Rep; 2017 Jul; 11(1):182. PubMed ID: 28750665
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
Gastaud L; Ambrosetti D; Otto J; Marquette CH; Coutts M; Hofman P; Esnault V; Favre G
Lung Cancer; 2013 Nov; 82(2):362-4. PubMed ID: 24001942
[TBL] [Abstract][Full Text] [Related]
10. Safety of dose-reduced pemetrexed in patients with renal insufficiency.
Hill J; Vargo C; Smith M; Streeter J; Carbone DP
J Oncol Pharm Pract; 2019 Jul; 25(5):1125-1129. PubMed ID: 29871545
[TBL] [Abstract][Full Text] [Related]
11. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.
Hellmann MD; Sturm I; Trnkova ZJ; Lettieri J; Diefenbach K; Rizvi NA; Gettinger SN
Clin Lung Cancer; 2015 Nov; 16(6):514-22. PubMed ID: 26003007
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.
Lal R; Hillerdal GN; Shah RN; Crosse B; Thompson J; Nicolson M; Vikström A; Potter VA; Visseren-Grul C; Lorenzo M; D'yachkova Y; Bourayou N; Summers YJ
Lung Cancer; 2015 Aug; 89(2):154-60. PubMed ID: 26101013
[TBL] [Abstract][Full Text] [Related]
13. Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
Izzedine H; Escudier B; Rouvier P; Gueutin V; Varga A; Bahleda R; Soria JC
Ann Oncol; 2013 Sep; 24(9):2421-5. PubMed ID: 23798615
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed disodium for the treatment of NSCLC: an update.
Hsu JY; Wakelee H
Drugs Today (Barc); 2008 Sep; 44(9):669-78. PubMed ID: 19137122
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed-induced scleroderma-like conditions in the lower legs of a patient with non-small cell lung carcinoma.
Ishikawa K; Sakai T; Saito-Shono T; Miyawaki M; Osoegawa A; Sugio K; Ono A; Mori H; Nishida H; Yokoyama S; Okamoto O; Fujiwara S; Hatano Y
J Dermatol; 2016 Sep; 43(9):1071-4. PubMed ID: 26992088
[TBL] [Abstract][Full Text] [Related]
16. [Pemetrexed nephrotoxicity].
Izzedine H
Bull Cancer; 2015 Feb; 102(2):190-7. PubMed ID: 25641712
[TBL] [Abstract][Full Text] [Related]
17. Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature.
Brandes JC; Grossman SA; Ahmad H
Cancer Invest; 2006; 24(3):283-7. PubMed ID: 16809156
[TBL] [Abstract][Full Text] [Related]
18. Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.
Sakhri L; Pinsolle J; Moro-Sibilot D; Pluchart H
J Med Case Rep; 2017 Sep; 11(1):262. PubMed ID: 28915906
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
20. Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions.
Elsoueidi R; Lander MJ; Richa EM; Adane ED
J Oncol Pharm Pract; 2016 Apr; 22(2):271-4. PubMed ID: 25908647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]